Takaoka Akinori, Yanai Hideyuki, Kondo Seiji, Duncan Gordon, Negishi Hideo, Mizutani Tatsuaki, Kano Shin-Ichi, Honda Kenya, Ohba Yusuke, Mak Tak W, Taniguchi Tadatsugu
Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.
Nature. 2005 Mar 10;434(7030):243-9. doi: 10.1038/nature03308. Epub 2005 Jan 23.
The activation of Toll-like receptors (TLRs) is central to innate and adaptive immunity. All TLRs use the adaptor MyD88 for signalling, but the mechanisms underlying the MyD88-mediated gene induction programme are as yet not fully understood. Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5-/- mice), the induction of these cytokines by various TLR ligands is severely impaired, whereas interferon-alpha induction is normal. We also provide evidence that IRF-5 interacts with and is activated by MyD88 and TRAF6, and that TLR activation results in the nuclear translocation of IRF-5 to activate cytokine gene transcription. Consistently, Irf5-/- mice show resistance to lethal shock induced by either unmethylated DNA or lipopolysaccharide, which correlates with a marked decrease in the serum levels of proinflammatory cytokines. Thus, our study identifies IRF-5 as a new, principal downstream regulator of the TLR-MyD88 signalling pathway and a potential target of therapeutic intervention to control harmful immune responses.
Toll样受体(TLRs)的激活是先天性免疫和适应性免疫的核心。所有TLRs都利用接头蛋白MyD88进行信号传导,但MyD88介导的基因诱导程序的潜在机制尚未完全了解。在这里,我们证明转录因子IRF-5通常参与TLR-MyD88信号通路的下游,用于诱导促炎细胞因子如白细胞介素-6(IL-6)、IL-12和肿瘤坏死因子-α的基因表达。在Irf5基因缺陷小鼠(Irf5-/-小鼠)的造血细胞中,各种TLR配体对这些细胞因子的诱导严重受损,而α干扰素的诱导正常。我们还提供证据表明,IRF-5与MyD88和TRAF6相互作用并被其激活,并且TLR激活导致IRF-5的核转位以激活细胞因子基因转录。一致地,Irf5-/-小鼠对未甲基化DNA或脂多糖诱导的致死性休克具有抗性,这与促炎细胞因子血清水平的显著降低相关。因此,我们的研究确定IRF-5是TLR-MyD88信号通路的一个新的主要下游调节因子,也是控制有害免疫反应的治疗干预的潜在靶点。